New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges (Q30407424)

21 June 2017

1 reference

title

New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges (English)

1 reference

21 June 2017

1 reference

John Steel

1

1 reference

21 June 2017

1 October 2011

1 reference

21 June 2017

1 reference

21 June 2017

25

1 reference

21 June 2017

285-298

1 reference

21 June 2017

5

1 reference

Mortality associated with influenza and respiratory syncytial virus in the United States

21 June 2017

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza-associated hospitalizations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza pandemics of the 20th century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Pandemic influenza in 1957; review of international spread of new Asian strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Emergence and pandemic potential of swine-origin H1N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

The annual production cycle for influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Evolutionary dynamics and emergence of panzootic H5N1 influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Emergence and predominance of an H5N1 influenza variant in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Role of domestic ducks in the propagation and biological evolution of highly pathogenic H5N1 influenza viruses in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Avian influenza A (H5N1) infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Re-emergence of fatal human influenza A subtype H5N1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Pandemic influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Generation of influenza A viruses entirely from cloned cDNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

A DNA transfection system for generation of influenza A virus from eight plasmids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

An improved reverse genetics system for influenza A virus generation and its implications for vaccine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Vaccines against pandemic influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza A Virus Lacking the NS1 Gene Replicates in Interferon-Deficient Systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Attenuation of equine influenza viruses through truncations of the NS1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Amelioration of influenza virus pathogenesis in chickens attributed to the enhanced interferon-inducing capacity of a virus with a truncated NS1 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Attenuated influenza virus vaccines with modified NS1 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Rewiring the RNAs of influenza virus to prevent reassortment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Tyrosines in the influenza A virus M2 protein cytoplasmic tail are critical for production of infectious virus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Extending the cytoplasmic tail of the influenza a virus M2 protein leads to reduced virus replication in vivo but not in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza A virus with defective M2 ion channel activity as a live vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza A virus lacking M2 protein as a live attenuated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Live bivalent vaccine for parainfluenza and influenza virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Cell-culture-derived influenza vaccine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

FluBlok, a next generation influenza vaccine manufactured in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

FluBlok, a recombinant hemagglutinin influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza vaccines based on virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza virus-like particles as pandemic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Induction of long-term protective immune responses by influenza H5N1 virus-like particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza virus-like particles containing M2 induce broadly cross protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Coated microneedles for transdermal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

DNA vaccines against influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Recombinant vectors as influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Comparative immunogenicity of recombinant adenovirus-vectored vaccines expressing different forms of hemagglutinin (HA) proteins from the H5 serotype of influenza A viruses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Pandemic H5N1 influenza vaccine development: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Programming the magnitude and persistence of antibody responses with innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Antibody recognition of a highly conserved influenza virus epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

A highly conserved neutralizing epitope on group 2 influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Influenza virus vaccine based on the conserved hemagglutinin stalk domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256169

21 January 2018

Identifiers

DOI

10.1007/BF03256169

1 reference

21 June 2017

1 reference

PubMed ID

21942913